Lightnews — Scholar-powered news

Remix Therapeutics @remixtx.bsky.social · 1d

Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy

1 3

Remix Therapeutics @remixtx.bsky.social · 5d

Join us next week for the @bloodcancerunited.bsky.social Light the Night Boston! We will be walking with thousands of others to honor those affected by blood cancers for greater awareness, research & support. #LightTheNight #LLS #RemixTherapeutics
Learn more: bit.ly/3VVRuo8

Remix Therapeutics @remixtx.bsky.social · 15d

Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches.

➡️ More here: bit.ly/3VGrT2o

2 2

Remix Therapeutics @remixtx.bsky.social · 27d

📣 Remix Chief Scientific Officer, Dominic Reynolds, PhD, will be speaking at the Small Molecules Targeting RNA & DNA Conference during the Discovery on Target event in Boston Sept 23-24. #RNAtherapeutics #RNAdegraders #RNAdegradation #mRNA #OncologyResearch

Remix Therapeutics @remixtx.bsky.social · Sep 10

Hear from Remix’s Maria Alexis, Principal Scientist, Computational Biology, about the team’s published work on poison exons & how deeper insights into RNA biology are shaping the future of medicine.
➡️http://bit.ly/4pcj0v5

1 1

Remix Therapeutics @remixtx.bsky.social · Sep 3

#BloodCancerAwarenessMonth is an important time to support patients and accelerate progress. Our lead program, REM-422, is in development for AML, which is one of the hardest-to-treat blood cancers with limited, effective treatment options.

Remix Therapeutics @remixtx.bsky.social · Aug 27

Our team’s work to enable the discovery of small molecule modulators of mRNA processing to quantify transcript levels of multiple independent target genes within a single HTS campaign was published this week in ASSAY and Drug Development Technologies.
Read more: bit.ly/45QKz4a

Remix Therapeutics @remixtx.bsky.social · Aug 19

Today, we were honored to host cancer survivor and advocate Coney Flowers at Remix as we gear up for the #LightTheNight walk with The Leukemia & Lymphoma Society. Her story inspired hope and strengthened our commitment to new treatments for patients with blood disorders. Thank you, Coney!

Remix Therapeutics @remixtx.bsky.social · Aug 13

Excellent discussion at the Canaccord Genuity 45th Annual Growth Conf, including our innovative REMaster discovery platform, the importance of targeting MYB as a driver of disease, the advancing clinical trials of REM-422 in ACC and AML, and our broader pipeline and partnerships.

1

Remix Therapeutics @remixtx.bsky.social · Aug 5

Remix CEO and Co-Founder, Pete Smith will be taking part in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference in Boston next week. #RemixTherapeutics

1

Remix Therapeutics @remixtx.bsky.social · Jul 21

MYB is an oncogenic transcription factor that is dysregulated in cancers like ACC, AML, and HR-MDS. Our lead program, REM-422, is an oral mRNA degrader that reduces MYB mRNA and protein expression, resulting in antitumor activity in MYB-dependent human tumor models.
➡️http://bit.ly/4kJkYQ4

1 1

Remix Therapeutics @remixtx.bsky.social · Jul 10

📣Next week, Co-Founder & CEO, Pete Smith, will be presenting on an Oncology panel and part of a Q&A session at Evercore's Emerging Private Biotech Conference. Looking forward to discussing Remix’s approach to tackling diseases by modulating RNA processing with small molecules. #Evercore #REM422

Remix Therapeutics @remixtx.bsky.social · Jun 24

🌈 Proud to welcome OUTbio Founder Ramsey Johnson for a powerful session on OUTbio’s mission to empower LGBTQ professionals and allies across the industry. At Remix, we’re committed to fostering a culture of inclusion, authenticity, and belonging—within our walls and across biotech. Thank you!

1

Remix Therapeutics @remixtx.bsky.social · Jun 17

Data presented in poster sessions at the @theaacr.bsky.social and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML.

Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D

Remix Therapeutics @remixtx.bsky.social · Jun 14

See you at BIO International next week! Heather Wasserman, Remix's CBO/COO will be onsite and looking forward to meeting with current partners and networking with new colleagues about Remix's innovative approach to addressing the intractable drivers of disease. #OncologyResearch #BIO2025

2

Remix Therapeutics @remixtx.bsky.social · Jun 9

Sarah Sirin, Director & Head of Computational Chemistry, participated in Scientific Computing World’s roundtable on the data impact of working with emerging modalities, like RNA therapeutics and protein degraders.
Learn more: bit.ly/3ZmPmbg

Remix Therapeutics @remixtx.bsky.social · Jun 2

Learn more about Remix’s innovative approach to drug design. Head of Medicinal Chemistry, Benoit Moreau, will be speaking at the 2nd Structure Based Drug Design Summit Meeting & the Precision in Drug Discovery & Preclinical Summit: bit.ly/42KveRd
bit.ly/3Y9k1YT

Remix Therapeutics @remixtx.bsky.social · May 28

Closing out #mentalhealthmonth, we reflect on how we create a healthier, more human workplace at Remix - staying grounded and connected as a team by focusing on our mission while recharging with things like yoga, volunteering on the Charles, and showing up in green to support the cause.

Remix Therapeutics @remixtx.bsky.social · May 22

This week, we hosted students from EVkids, a nonprofit that supports Boston youth, for a hands-on intro to biotech at Remix! From extracting a strawberry's DNA to learning how AI powers drug discovery, they explored the many career paths science has to offer. Grateful to be part of their journey!👨‍🔬🧬

Remix Therapeutics @remixtx.bsky.social · May 20

Hear from Dom Reynolds, our Chief Scientific Officer, about his perspective on how Remix is tackling one of the biggest factors in being able to treat cancer and other difficult to treat diseases - undruggable proteins. bit.ly/3H5dsAX
#OncologyResearch #ACC #AdenoidCysticCarcinoma #AML

Remix Therapeutics @remixtx.bsky.social · May 16

Preclinical data evaluating anti-tumor activity of our lead program REM-422, a first-in-class degrader of the MYB oncogene, in xenograft models of AML has been selected for a poster presentation at the European Hematology Association 2025 Congress next month. bit.ly/4mhxTuD
#EHA2025

1

Remix Therapeutics @remixtx.bsky.social · May 6

📣Our CSO, Dom Reynolds, will be speaking tomorrow at the 5th Workshop on Splicing Factor Mutations and RNA Biology in Cancer, bringing together leaders in the research community for collaborative discussions to advance the field and new pathways for treatments.
#OncologyResearch

1

Remix Therapeutics @remixtx.bsky.social · May 5

📣 Benoit Moreau, Remix’s Head of Medicinal Chemistry, will be the Roundtable facilitator for the “From PROTACs to RNA-Modulated Degraders: Engineering Novel Therapeutics for Hard-to-Target Proteins” session.
➡https://bit.ly/3RroSRu

1 1

Remix Therapeutics @remixtx.bsky.social · Apr 30

CEO Pete Smith had an opportunity to participate in the “Drugging the Undruggable/Transcription Factors” panel at #AACR25. We're proud of Remix’s contributions in this field & hope to continue the conversation. Thank you Jonathan Chang/Leerink, the panelists & MPM BioImpact for a great discussion!

2

Remix Therapeutics @remixtx.bsky.social · Apr 28

Charles Kung, PhD, presenting REM-422, a first-in-class, orally available small molecule degrader of MYB mRNA at #AACR today. REM-422 induces tumor regressions in MYB-dysregulated preclinical models at well tolerated doses & is in two Phase 1 clinical trials. bit.ly/4c4FkAr

2 3